Is Caprolactam Chem overvalued or undervalued?

As of 15 September 2025, the valuation grade for Caprolactam Chem has moved from expensive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of -21.12, an EV to EBITDA of 12.82, and a Price to Book Value of 4.37. These ratios suggest that while the company is not generating profits currently, its valuation metrics are more aligned with its peers in the industry. In comparison to its peers, Caprolactam Chem's valuation appears more favorable than Sun Pharma, which has a PE ratio of 33.52 and an EV to EBITDA of 22.67, and Divi's Lab, which is even more expensive with a PE of 69.55. Notably, the company has a PEG ratio of 0.00, indicating no growth expectations priced in, which could suggest potential upside if the company returns to profitability. Despite recent underperformance compared to the Sensex, with a year-to-date return of -16.66% versus the Sensex's 4.67%, the long-term performance over five years shows a significant gain of 182.58%, reinforcing the potential for recovery and value realization.